Literature DB >> 3925128

Role of hemoglobin in the differential biotransformation of glyceryl trinitrate and isosorbide dinitrate by human erythrocytes.

B M Bennett, J F Brien, K Nakatsu, G S Marks.   

Abstract

Incubation of 2 X 10(-7) M glyceryl trinitrate (GTN) at 37 degrees C with human red blood cells resuspended in saline resulted in a 73.4 +/- 3.5% (S.D.) elimination of GTN after 10 min. The elimination of GTN was accompanied by the appearance of an equimolar amount of the GTN metabolites. The biotransformation of GTN and another organic nitrate, isosorbide dinitrate (ISDN), was examined in more detail using the 25,000 X g supernatant fraction of human red blood cells (RBC-SF). Incubation of 2 X 10(-7) M GTN or ISDN at 37 degrees C with RBC-SF resulted in a 46.3 +/- 7.3% (S.D.) elimination of GTN after 40 min and a 51.8 +/- 5.9% (S.D.) elimination of ISDN after 240 min. The elimination of the parent organic nitrate was accompanied by the appearance of an equimolar amount of metabolites. The biotransformation of ISDN was inhibited completely by pretreatment of the RBC-SF with trypsin, N-ethylmaleimide or heating at 65 degrees C, whereas GTN biotransformation was only inhibited partially by these treatments. Biotransformation of GTN was inhibited partially by pretreatment of the RBC-SF with CO or potassium ferricyanide; these treatments had no effect on ISDN biotransformation. Treatment of the RBC-SF with the combination of N-ethylmaleimide plus CO or trypsin plus CO resulted in complete inhibition of GTN biotransformation. We conclude that ISDN biotransformation by erythrocytes is a sulfhydryl-dependent enzymatic process, whereas the biotransformation of GTN is due to a combination of a sulfhydryl-dependent enzymatic process and an interaction with reduced hemoglobin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925128

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

Review 1.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo.

Authors:  David R Janero; Nathan S Bryan; Fumito Saijo; Vijay Dhawan; David J Schwalb; Michael C Warren; Martin Feelisch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-18       Impact factor: 11.205

Review 3.  Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.

Authors:  D Salvemini; A Pistelli; E Anggard
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.